Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/23/2013EP2651898A1 Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
10/23/2013EP2651895A1 Oxime compounds as hdl-cholesterol raising agents
10/23/2013EP2651894A1 Thiosemicarbazone compounds and use in the treatment of cancer
10/23/2013EP2651893A1 Sulfur derivatives as chemokine receptor modulators
10/23/2013EP2651891A1 Bicyclic ring system substituted amide functionalised phenols as medicaments
10/23/2013EP2651888A1 New compounds for the treatment of neurodegenerative diseases
10/23/2013EP2651887A1 Novel compounds for the treatment of neurodegenerative diseases
10/23/2013EP2651885A1 Anti-viral compounds
10/23/2013EP2651878A1 Cyclohexane compounds and their use as antibiotics
10/23/2013EP2651864A1 Methods and devices for using isoperillyl alcohol
10/23/2013EP2651450A2 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
10/23/2013EP2651446A1 Preparation comprising insulin, nicotinamide and an amino acid
10/23/2013EP2651442A2 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
10/23/2013EP2651429A2 Neuropeptide analogs, compositions, and methods for treating pain
10/23/2013EP2651427A1 Novel therapeutic strategies for improving an anticancer treatment
10/23/2013EP2651420A2 Peptide-based in vivo sirna delivery system
10/23/2013EP2651419A1 A composition comprising an antibiotic and a dispersant or an anti -adhesive agent
10/23/2013EP2651418A1 Composition usable in the treatment of cellular degeneration
10/23/2013EP2651417A1 Ask1 inhibiting pyrrolopyrimidine derivatives
10/23/2013EP2651416A1 Compounds useful for treating aids
10/23/2013EP2651415A1 Gastric and colonic formulations and methods for making and using them
10/23/2013EP2651414A1 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
10/23/2013EP2651413A1 Novel inhibitors of matrix metalloproteinases
10/23/2013EP2651412A2 Androgen receptor inhibitors and methods of use thereof
10/23/2013EP2651411A2 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
10/23/2013EP2651410A1 Transdermal therapeutic system for administering an active substance
10/23/2013EP2651409A1 Novel pharmaceutical formulation comprising nsaid and cyclodextrin
10/23/2013EP2651408A1 S1p receptor agonists and use thereof in treating hiv infections
10/23/2013EP2651407A2 3-methanesulfonylpropionitrile for treating inflammation and pain
10/23/2013EP2651406A1 Composition containing resveratrol, l-tryptophan, l-aspartic acid and vitamin b3 for use in the pharmaceutical, nutritional and cosmetic fields
10/23/2013EP2651405A2 Casein kinase 1 (ck1 ) inhibitors
10/23/2013EP2651404A2 Casein kinase 1delta (ck1delta) inhibitors
10/23/2013EP2651403A2 Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
10/23/2013EP2651402A1 Process for preparing nanoparticles of two polyamino acids of opposite charge, one of the two of which is in charge surplus
10/23/2013EP2651401A2 Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin
10/23/2013EP2651400A2 Controlled release oral dosage forms of poorly soluble drugs and uses thereof
10/23/2013EP2651395A1 Pharmaceutical compositions of selective factor xa inhibitors for oral administration
10/23/2013EP2651392A1 Solid compositions containing nonsteroidal anti-inflammatory drugs, the processes for their preparation and their use.
10/23/2013EP2651391A1 Pharmaceutical composition for oral administration intended to prevent misuse
10/23/2013EP2651390A1 Zolpidem-based orodispersible pharmaceutical tablet
10/23/2013EP2651389A1 Terpenoid spiro ketal compounds with lxr agonists activity, their use and formulations with them
10/23/2013EP2651375A2 Leave-on non-solid skin conditioning compositions containing 12-hydroxystearic acid and ethoxylated hydrogenated castor oil
10/23/2013EP2651251A1 Composition for the treatment of metabolic disorders
10/23/2013EP2651250A1 Use of vitamin k for weight maintenance and weight control
10/23/2013EP2651248A2 Functional food preparation and use thereof
10/23/2013EP2651225A2 A process for preparation of praziquantel
10/23/2013EP2651222A1 Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
10/23/2013EP2651221A1 Methods of producing and using brassinosteroids to promote growth, repair and maintenance of skeletal muscle and skin
10/23/2013EP1842557B1 Drug carrier and drug carrier kit for inhibiting fibrosis
10/23/2013CN103370416A Modified single-strand polynucleotide
10/23/2013CN103370414A Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas
10/23/2013CN103370329A Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof
10/23/2013CN103370326A Phosphorous derivatives as chemokine receptor modulators
10/23/2013CN103370322A 2-substituted imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment of hyperproliferative disorders
10/23/2013CN103370321A Substituted pyrimido[1,2-b]indazoles and their use as modulators of the PI3K/AKT pathway
10/23/2013CN103370320A Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
10/23/2013CN103370318A Substituted imidazopyridazines
10/23/2013CN103370317A Imidazo [4, 5-c] quinolin-1-yl derivative useful in therapy
10/23/2013CN103370316A 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines as inhibitors of cell proliferation and the use thereof
10/23/2013CN103370315A Compositions and methods for modulating farnesoid x receptors
10/23/2013CN103370314A Substituted benzopyrazin derivatives as FGFR kinase inhibitors for the treatment of cancer diseases
10/23/2013CN103370311A Pochoxime conjugates useful for the treatment of HSP90 related pathologies
10/23/2013CN103370309A Substituted N-phenethyltriazoloneacetamides and use thereof
10/23/2013CN103370308A Thiosemicarbazone compounds and use in the treatment of cancer
10/23/2013CN103370307A Sulphonamide compounds and methods of making and using same
10/23/2013CN103370289A 4-hydroxybutyric acid deuterated analogs
10/23/2013CN103370102A Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
10/23/2013CN103370071A Long wearing powder-based cosmetic compositions
10/23/2013CN103370070A Novel antibacterial compounds, methods of making them, and uses thereof
10/23/2013CN103370069A Method and formulations for treating sialic acid deficiencies
10/23/2013CN103370068A Treatment of JAK2-mediated conditions
10/23/2013CN103370067A Novel oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
10/23/2013CN103370066A Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer
10/23/2013CN103370065A Novel benzyl azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
10/23/2013CN103370064A Drug formulations using water soluble antioxidants
10/23/2013CN103370063A Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
10/23/2013CN103370062A Composition to increase joint and/or postural stability
10/23/2013CN103370061A Skin therapy systems
10/23/2013CN103370060A Treatment of cancer/inhibition of metastasis
10/23/2013CN103370059A A drug delivery device
10/23/2013CN103370058A Encased tamper resistant controlled release dosage forms
10/23/2013CN103370056A Absorbent dressings with painkilling activity
10/23/2013CN103370055A Long-lasting controlled-release liposome composition and method for producing same
10/23/2013CN103370054A Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes
10/23/2013CN103370053A Carotenoid particles and uses thereof
10/23/2013CN103369974A Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
10/23/2013CN103369961A Bicyclo[3.2.1]octyl amide derivatives and uses of same
10/23/2013CN103361388A L-cyclic alkylamino acid synthesis method and medicinal composition containing L-cyclic alkylamino acid
10/23/2013CN103361276A Saccharopolyspora spinosa HBERC-25376, culturing method thereof as well as separation method and application of active substances thereof
10/23/2013CN103360457A Androstanedione derivative crystal form and preparation method therefor
10/23/2013CN103360456A Triterpenoid compounds, and preparation and application thereof
10/23/2013CN103360453A Preparation of tetracyclic triterpene compound and anti-aging application
10/23/2013CN103360452A Preparation and application of pedicellus melo tetracyclic triterpenoid cucurbitacin type compound
10/23/2013CN103360451A Preparation of cucurbitacin compounds and application of cucurbitacin compounds to medicines
10/23/2013CN103360448A Single crystal form of metacavir ethanol solvent compound and preparation method thereof
10/23/2013CN103360447A Macrolide solid-state forms
10/23/2013CN103360446A Macrolide solid-state forms
10/23/2013CN103360445A Macrolide solid-state forms
10/23/2013CN103360440A Antibacterial aminoglycoside analogs
10/23/2013CN103360427A Three-nitrogen dynamic platinum compound as well as preparation method and application thereof
1 ... 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 ... 7860